Bristol-Myers Announces FDA Accepts Application For Opdivo Plus Low-Dose Yervoy For Treatment of First-Line Non-Small Cell Lung Cancer In Patients With Tumor Mutational Burden ≥10 mut/Mb
luke@benzinga.com